Business
OWC Pharmaceutical Research Corp. Announces Update on its Proprietary Medical Cannabis Sublingual Tablet
OWC Pharmaceutical Research Corp. Announces Update on its Proprietary Medical Cannabis Sublingual Tablet.
About this update from Owc Pharmaceutical Research Corp
[{"type":"text","content":"\n\n\n\nOWC Pharmaceutical Research Corp. Announces Update on its Proprietary Medical Cannabis Sublingual Tablet\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\n\nOWC Pharmaceutical Research Corp. Announces Update on its Proprietary Medical Cannabis Sublingual Tablet\nPR Newswire\nPETACH TIKVA, Israel, Dec. 21, 2017\n\n\n\nPETACH TIKVA, Israel, Dec. 21, 2017 /PRNewswire/ -- In December 2017, OWC Pharmaceutical Research Corp (OTCQB: OWCP) received a new permit from the Israel Medical Cannabis Agency [MCA] to proceed with the safety study of their oral disintegrating tablet. The study protocol will be submitted to the Institutional Review Board [IRB] at a leading Israeli academic hospital in the coming weeks. The study is scheduled to start in Q2 2018.\n\n\nIn October of 2016 OWC announced that it had completed the development of a proprietary cannabinoid-enriched sublingual tablet (the \"Tablet\") for the administration of medical cannabis. The Tablet constitutes a smoke-free alternative for patients using medical cannabis.\n\nThe technology behind the Tablet is protected and provides for the ingestion of virtually any dosage of medical cannabis with a sublingual delivery mechanism, whereby the compounds are absorbed directly into the patient's blood through the oral epithelial tissue. The Tablet also enables physicians to safely and accurately gauge and monitor the dosage and treatment of each individual patient, something that is essentially impossible to do for patients who administer cannabis by smoking.\n\nThe Cannabis Tablet provides several benefits:\n\n\nIt provides a delivery modality which avoids all the disadvantages of smoking regular tobacco products, including the danger of lung cancer and general damage to the respiratory system\nNo significant smell\nFixed dosage\nEase of use\nThe sublingual Tablet will be indicated mainly for chronic pain patients suffering from diseases such as Fibromyalgia or neuropathic pain and PTSD patients. The Tablet dissolves within the mouth allowing it to absorb through the oral mucosa and thus skips the first pass through th...